Biopharmaceutical Company Launches Meniere's Disease Treatment Study

For Immediate Release

July 8, 2016

STUDY LAUNCHED FOR MÉNIÈRE’S DISEASE TREATMENT

Seeking Patients to Enroll in Study to Treat Vertigo-Inducing Disease

Cary, NC (July 8, 2016) – Meniere’s disease often lacks the recognition value of other diseases that may affect hearing. More than 600,000 people in the US suffer from Meniere’s disease, a disorder of the inner ear which can affect balance and hearing. Meniere’s disease patients suffer from vertigo attacks (a feeling that the patient’s surroundings are moving), dizziness, nausea, hearing loss, and ringing in the ears. Currently, there is no known cure for Meniere’s disease and there are currently no FDA-approved drug treatments.

Otonomy, a biopharmaceutical company dedicated to innovative treatments for Meniere’s disease, has begun to enroll patients in a 16-week research study at multiple clinical sites across the US to evaluate the safety and effectiveness of an investigational drug for Meniere’s disease. Otonomy is currently seeking patients aged 18-85 who have been diagnosed with unilateral (one ear only) Meniere’s disease and have documented hearing loss to participate in the research study.

Locally, this research study is being conducted at Cary Medical Group. Study participants will receive study-related exams, lab tests, and investigational medication at no charge. For more information about this study and to see if you may qualify, call 888-205-5801 or visit www.OtonomyResearch.com.

###